Amanote Research
Register
Sign In
Php35 - Amnog Early Benefit Assessment (Eba) and Market Penetration of New Drugs for Melanoma, Multiple Sclerosis and Diabetes Mellitus in Germany
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.931
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
J. Mathes
A. Höer
Publisher
Elsevier BV